From one of the slides it sounds like not too soon. I will try to listen to the HC Wainwright CC tomorrow and see if they give any additional clues.
It's at 11 AM.
RG-012, Anti-miR-21 for the Treatment of Alport SyndromePhase 2 Currently Enrolling Patients
Chronic treatment with RG-012 is well tolerated (Q2W for one year)
Clinical demonstration of desired exposure and modulation of microRNA target in kidney
Sanofi has assumed development responsibility; initiation and recruitment for Phase 2 study underway. Regulus believes new site initiation and patient enrollment has been impacted by COVID-19 pandemic
Partnership recently restructured providing for $5m in revised milestones upon receipt of RG-012 materials and remaining $5m upon achievement of interim enrollment milestone. Regulus eligible to receive additional $25M development milestone.
Achievement of Sanofi milestone payments to pay down venture debt with potential for additional seven months of interest-only payments through 2021